Steve Jennings to Speak at CPHI Milan 2026

Jenerise Ltd. announced that Co-Founder and CEO Steve Jennings will speak on a panel at CPHI Milan 2026, one of the pharmaceutical and nutraceutical industry's leading global events. The panel, titled "Nutraceuticals: Scaling Without Breaking Supply," will take place on Thursday, October 8, 2026, from 10:30–11:15 AM (CEST) in the Supply & Formulation Excellence Theatre.

The session will examine the operational and regulatory pressures reshaping the nutraceutical sector, including diversifying ingredient sourcing amid rising tariff pressure, navigating an increasingly fragmented global regulatory landscape, and redefining what "proof" means for the next generation of functional health products.

Jennings brings a distinctive perspective to the panel, shaped by more than three decades at the intersection of performance and product innovation. A former professional cyclist, he launched Ergomax C150 in 1992 (the world's first creatine monohydrate brand), helping to pioneer an entire product category that remains foundational to the sports nutrition industry today. That early experience continues to inform his approach at Jenerise, where he now leads the development of the Jenerise Cr.01™ brand and the company's expanding international B2B creatine distribution network.

Jenerise Co-Founder Rachael Jennings will also be on-site at CPHI Milan 2026, joining Steve to meet with existing and prospective brand partners throughout the event.

Meet the Jenerise Team at CPHI Milan

Steve and Rachael will be available for in-person meetings throughout the CPHI Milan event. Partners, distributors, and industry stakeholders interested in scheduling time with the team are encouraged to reach out directly.

To arrange a meeting, contact Rachael Jennings at rachael@jenerise.com.